Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,671–1,680 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1671
- Medicine slug
- zoledronic-acid
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 35
- Source count
- 14
- Agreement rate
- 0.928571
- Recorded readings
28%
- Numeric value
- 28
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5f96d4-f87c-4968-bed0-a4b5e77f4162 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8e02635-4473-8ba2-248f-ced58dbeabce (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd0324d8-b9bd-fd4c-e053-6394a90a5465 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9b3737-9ce6-4a89-b76e-6aab79eba9cf (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de65a7f-a219-4b22-9155-61fedc84433b (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80006f10-85a3-4390-b5dc-3b2097134f3d (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac81ae-f92c-4f0b-b480-44badf72b5f5 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f94a5c9e-74bc-d09e-cd65-394b2a5de2ad (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:824eaeee-6b3d-4d62-b268-77f8bd8e7f10 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1977d713-4cc7-405e-b4c1-a9a91635eff6 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d761011b-edd6-4d3f-bacd-8607dc2414fc (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fcf8c9-ef8a-4e93-9ee6-acfadd35a861 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164500d7-51cf-438a-8bee-7a7dce76ad7a (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b165df31-52f0-d67f-71e7-f3b4f18d2f15 (opens source in a new tab)
Zoledronic Acid label
Version not recorded · Effective date not recorded
In vitro, the plasma protein binding is low, with the unboundfraction ranging from 60% at 2 ng/mL to 77% at 2,000 ng/mL of zoledronic acid.
Projected row 1672
- Medicine slug
- zolmitriptan
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 0.8
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca7d28-8322-f151-e053-6394a90a39b7 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fcdc5d6-38fa-458d-a581-4e3678a9e8fd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca22bf-caf1-89af-e053-6394a90a2987 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a32fc6-4243-9cdd-91c7-b8a58e0f9811 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd6203d4-02b5-43b2-9460-16a4d932ed51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6628b7a-0b63-4e6f-a5e7-2fa195265235 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d977430-f494-415d-9daf-3c3163156249 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b37962f-253b-4dc9-9ed2-ff44d2370e51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a734b368-6008-441c-ab44-5634e46be9a4 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fc95729-2f5d-4d5c-b26c-3a13854f73e3 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75a92ce1-eade-4b71-80ab-d7fd1f57e352 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0040a6-b1d6-3d73-e063-6294a90af23c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5c5cb44-7581-4856-8324-13c02a6101dd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8d657ac-dbda-4455-8bb5-3896951c3b67 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89bfee8d-1ddf-4fb2-a565-ce32f096a25d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9212b076-b1ae-4c06-bd56-0ae3c5c9acdf (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e520fe-2f57-400b-8ee5-9a3f89037d6c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59bfbdd-7f4b-4a29-8396-e144dde65878 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333caafc-2e63-49f8-a0c6-534e528d228d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c970dd17-abdb-4fac-8de8-984e388b498c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Mean absolute bioavailability is approximately 40%.
102%
- Numeric value
- 102
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a6924da-37a0-4e43-b57d-410b5179361b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean relative bioavailability of the nasal spray formulation is 102%, compared with the oral tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e12658-eb42-4d1f-9192-9c4298416d51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean relative bioavailability of the nasal spray formulation is 102%, compared with the oral tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a40502-149d-41bd-966e-771e937a955b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean relative bioavailability of the nasal spray formulation is 102%, compared with the oral tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b4e77de-3185-4d1e-946a-96b785b76da0 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean relative bioavailability of the nasal spray formulation is 102%, compared with the oral tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e304c986-24fa-451e-a560-0af658ba387b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean relative bioavailability of the nasal spray formulation is 102%, compared with the oral tablet.
Projected row 1673
- Medicine slug
- zolmitriptan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca7d28-8322-f151-e053-6394a90a39b7 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fcdc5d6-38fa-458d-a581-4e3678a9e8fd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca22bf-caf1-89af-e053-6394a90a2987 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a6924da-37a0-4e43-b57d-410b5179361b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a32fc6-4243-9cdd-91c7-b8a58e0f9811 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd6203d4-02b5-43b2-9460-16a4d932ed51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6628b7a-0b63-4e6f-a5e7-2fa195265235 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d977430-f494-415d-9daf-3c3163156249 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b37962f-253b-4dc9-9ed2-ff44d2370e51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a734b368-6008-441c-ab44-5634e46be9a4 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fc95729-2f5d-4d5c-b26c-3a13854f73e3 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75a92ce1-eade-4b71-80ab-d7fd1f57e352 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e12658-eb42-4d1f-9192-9c4298416d51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0040a6-b1d6-3d73-e063-6294a90af23c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5c5cb44-7581-4856-8324-13c02a6101dd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a40502-149d-41bd-966e-771e937a955b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b4e77de-3185-4d1e-946a-96b785b76da0 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8d657ac-dbda-4455-8bb5-3896951c3b67 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89bfee8d-1ddf-4fb2-a565-ce32f096a25d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9212b076-b1ae-4c06-bd56-0ae3c5c9acdf (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e520fe-2f57-400b-8ee5-9a3f89037d6c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e304c986-24fa-451e-a560-0af658ba387b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59bfbdd-7f4b-4a29-8396-e144dde65878 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333caafc-2e63-49f8-a0c6-534e528d228d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c970dd17-abdb-4fac-8de8-984e388b498c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.
Projected row 1674
- Medicine slug
- zolmitriptan
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca7d28-8322-f151-e053-6394a90a39b7 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and Cmax of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the Tmax is somewhat later with zolmitriptan orally disintegrating tablets, with a median Tmax of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fcdc5d6-38fa-458d-a581-4e3678a9e8fd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and Zolmitriptan Orally Disintegrating Tablets, but the T max is somewhat later with Zolmitriptan Orally Disintegrating Tablets, with a median T max of 3 hours for Zolmitriptan Orally Disintegrating Tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca22bf-caf1-89af-e053-6394a90a2987 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and Cmax of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the Tmax is somewhat later with zolmitriptan orally disintegrating tablets, with a median Tmax of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a32fc6-4243-9cdd-91c7-b8a58e0f9811 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd6203d4-02b5-43b2-9460-16a4d932ed51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablet, with a median T max of 3 hours for orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6628b7a-0b63-4e6f-a5e7-2fa195265235 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d977430-f494-415d-9daf-3c3163156249 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of ZOMIG tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the ZOMIG tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b37962f-253b-4dc9-9ed2-ff44d2370e51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a734b368-6008-441c-ab44-5634e46be9a4 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fc95729-2f5d-4d5c-b26c-3a13854f73e3 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75a92ce1-eade-4b71-80ab-d7fd1f57e352 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablet, with a median T max of 3 hours for orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0040a6-b1d6-3d73-e063-6294a90af23c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5c5cb44-7581-4856-8324-13c02a6101dd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablets compared with 1.5 hours for the zolmitriptan tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8d657ac-dbda-4455-8bb5-3896951c3b67 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89bfee8d-1ddf-4fb2-a565-ce32f096a25d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9212b076-b1ae-4c06-bd56-0ae3c5c9acdf (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and Zolmitriptan Orally Disintegrating Tablets, but the T max is somewhat later with Zolmitriptan Orally Disintegrating Tablets, with a median T max of 3 hours for Zolmitriptan Orally Disintegrating Tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e520fe-2f57-400b-8ee5-9a3f89037d6c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59bfbdd-7f4b-4a29-8396-e144dde65878 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333caafc-2e63-49f8-a0c6-534e528d228d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c970dd17-abdb-4fac-8de8-984e388b498c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The AUC and C max of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T max is somewhat later with zolmitriptan orally disintegrating tablets, with a median T max of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet.
Projected row 1675
- Medicine slug
- zolmitriptan
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 0.44
- Recorded readings
7 L/kg
- Numeric value
- 7
- Unit
- L/kg
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fcdc5d6-38fa-458d-a581-4e3678a9e8fd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd6203d4-02b5-43b2-9460-16a4d932ed51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6628b7a-0b63-4e6f-a5e7-2fa195265235 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a734b368-6008-441c-ab44-5634e46be9a4 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fc95729-2f5d-4d5c-b26c-3a13854f73e3 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75a92ce1-eade-4b71-80ab-d7fd1f57e352 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8d657ac-dbda-4455-8bb5-3896951c3b67 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89bfee8d-1ddf-4fb2-a565-ce32f096a25d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9212b076-b1ae-4c06-bd56-0ae3c5c9acdf (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333caafc-2e63-49f8-a0c6-534e528d228d (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c970dd17-abdb-4fac-8de8-984e388b498c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7 L/kg.
7.0 L/kg
- Numeric value
- 7
- Unit
- L/kg
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca7d28-8322-f151-e053-6394a90a39b7 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ca22bf-caf1-89af-e053-6394a90a2987 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a32fc6-4243-9cdd-91c7-b8a58e0f9811 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d977430-f494-415d-9daf-3c3163156249 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b37962f-253b-4dc9-9ed2-ff44d2370e51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0040a6-b1d6-3d73-e063-6294a90af23c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5c5cb44-7581-4856-8324-13c02a6101dd (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16e520fe-2f57-400b-8ee5-9a3f89037d6c (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59bfbdd-7f4b-4a29-8396-e144dde65878 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution is 7.0 L/kg.
8.4 L/kg
- Numeric value
- 8.4
- Unit
- L/kg
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a6924da-37a0-4e43-b57d-410b5179361b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution for zolmitriptan nasal spray formulation is 8.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e12658-eb42-4d1f-9192-9c4298416d51 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution for zolmitriptan nasal spray formulation is 8.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a40502-149d-41bd-966e-771e937a955b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution for zolmitriptan nasal spray formulation is 8.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b4e77de-3185-4d1e-946a-96b785b76da0 (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution for zolmitriptan nasal spray formulation is 8.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e304c986-24fa-451e-a560-0af658ba387b (opens source in a new tab)
Zolmitriptan label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution for zolmitriptan nasal spray formulation is 8.4 L/kg.
Projected row 1676
- Medicine slug
- zolpidem
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 117
- Source count
- 117
- Agreement rate
- 0.717949
- Recorded readings
9.9 hr
- Numeric value
- 9.9
- Unit
- hours
- Source records
- 84
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 84 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7abb6898-223c-487b-856c-068ac04f7a5c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.7) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c6cc45-c28b-729b-e053-2a95a90a7ccb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:747949c5-2c91-4909-8a07-71b6826f8e97 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47212207-52a1-938b-e063-6294a90abca8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67ef513-1b2c-42fe-bf33-4c7e9db191a3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89cfb1d5-437c-4c13-8f9b-b6851ffba87b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abdcf77-d3ed-42bc-acd9-545aab75d567 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e5208b-5109-58c6-e053-2995a90a994a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70d7cfc3-7e54-4cd8-8911-7cf115d5c820 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acfcfe91-83a0-44ab-95c0-dd98b73ac69a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.7), Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23bce69d-7918-42c2-8020-e22f292ff31f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cef5718-c562-43c3-8abe-a2fc5235ad2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc76ab4c-3607-39c3-e053-6394a90a6877 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.8), Use in Specific Populations ( 8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87b722-cdb7-0b17-e053-2a95a90a315b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.8), Use in Specific Populations (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413b6f65-101e-e2cf-0802-711d080b851b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0553e26c-f2aa-43aa-adf9-6eb951a501d3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87ae17-a3c5-a3a5-e053-2a95a90aa4b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.8), Use in Specific Populations ( 8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c859c752-8a85-2017-e053-2a95a90a771f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see DOSAGE AND ADMINISTRATION (2.2), WARNINGS AND PRECAUTIONS (5.8), USE IN SPECIFIC POPULATIONS (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74c4e793-3444-4d3d-8211-26374349ab1e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaca34da-2b12-4dd4-91b5-a8446c7bd41e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff2e7fc-2f7e-43c9-bfb3-d929ecc9eb72 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6db679f6-b1f8-4fbf-9e87-9cef4650c45a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in subjects with normal hepatic function of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f8488f3-851d-4111-af23-60f420aad0d6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1584bad1-7bf4-4805-bdd9-7eb0fac92721 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6ce23-e7b1-510e-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.7), Use in Specific Populations (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f43bde-efba-42be-adef-94e1ef6664fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2db3979-daa6-6e83-e053-2a95a90a3a2f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see DOSAGE AND ADMINISTRATION (2.2), WARNINGS AND PRECAUTIONS (5.8), USE IN SPECIFIC POPULATIONS (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e15d6e3-8d06-0936-e063-6394a90ab8db (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c58053-7ed8-4a3d-a2f7-8e30c4e5a367 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5679ed64-8424-4e63-a3c9-91d80fff2ca6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e2d31b-ce26-78b0-e053-2a95a90ac491 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf3dcbde-b92a-4802-98e4-14f00abdf99e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:507225e2-80ba-18c4-e054-00144ff88e88 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cc924a-26e0-431f-9160-32c9d92a46cd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fa86b79-8809-35f4-e063-6394a90a4377 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bbc3c35-2811-4a67-9dcc-5eed38ef8b52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda413e7-b1ae-312a-e053-6394a90ab2c6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91511d2f-7066-49a0-90ea-2940d955c85e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cc61da-838e-4add-b2d6-42b2b283a000 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76eb9d8-ca7d-4479-bd16-52a57f623b02 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8581cfad-525b-4b16-b116-a5138d9fda52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33094305-4bbd-4b52-9079-8853d5f83682 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8f7696-0d02-dd1f-e063-6394a90a5866 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb850154-4b4b-4d9a-8476-aea1a93fe8d7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba3c29f-3835-4f4f-a39f-56fb42686f5b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3882d72d-686b-406b-e063-6294a90a0b89 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bc8a122-aa21-212c-e063-6394a90a3bda (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5cf535-ccdc-ecd7-e063-6394a90a726e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e20f53-c042-eac0-e063-6394a90acfca (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c9a29c-a285-40d0-bf3a-7e8c944ee39c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68a1b3b-b3d1-495e-be46-466113e7dbd6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa7e88b-7929-45ac-9e81-03f4abf28e94 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac8c412a-0f94-7c3a-e053-2995a90afdc7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e13ad50-f846-813a-e063-6294a90a5878 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38c838a4-9943-445a-8e80-e823d56eeaa5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d34336b1-7041-4078-beda-94bc9d9f771e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83510333-f07d-4b81-a3ae-2801d114bd31 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df130798-1458-455b-a4e1-c33c4ecee43b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e534b3ac-1110-465f-8692-6ea585996fb6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b0ba48-4e71-25f7-e053-2a95a90aea82 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db735db9-1c82-4d32-bf91-97b05a75e876 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8adec28-9dcd-4a7e-e053-2a95a90a991e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.8), Use in Specific Populations ( 8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9f696a-b637-4dea-e063-6394a90aeb2e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9ac3d4e-f502-41e3-95c0-0d334584566d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( ), Warnings and Precautions ( ), Use in Specific Populations ( )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8572fd4-70c7-4c94-a0d7-9b4be6fa8f77 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7be7f243-e6f8-406f-aed7-be7cedd5630a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr). [see Dosage and Administration (2.2) , Warnings and Precautions (5.7) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e5b61b6-a5bd-4f09-9d34-905ce32f1899 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea2067bd-1622-4d98-8012-2c09405aa88d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25f1176d-5195-1a99-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dd113e1-f789-48d2-8cb2-d39b71273658 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349053e4-9885-ec0b-e063-6294a90ad79a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7da75d2b-905c-4fdf-bc53-1358c6477755 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2556c804-7a5e-4dbd-aeef-a3ba3a247c39 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c36cadf4-65a4-4466-b409-c82020b42452 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c108d1-5e2f-41c7-a845-2aed48c30905 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021153ce-fe27-4ed1-8d88-b4157b0ed734 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78481108-4a1c-fce9-e053-2a91aa0a09ad (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2), Warnings and Precautions (5.7), Use in Specific Populations (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87df4e-2c97-e23e-e053-2a95a90ab354 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see DOSAGE AND ADMINISTRATION (2.2), WARNINGS AND PRECAUTIONS (5.8), USE IN SPECIFIC POPULATIONS (8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f939549f-14a6-d37c-e053-6294a90a034a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.8), Use in Specific Populations ( 8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d579c6ca-c820-49ff-92fb-2e6aaad3b052 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3310d63e-d79a-175d-e063-6394a90a4270 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.7 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef72eb73-d058-4ca3-9013-691aae8426fb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:907c7b18-2638-512c-e053-2995a90ae6fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.7), Use in Specific Populations ( 8.7)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9922ce14-b418-4235-9c59-d674a8e70210 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr) [see Dosage and Administration (2.2) , Warnings and Precautions (5.8) , Use in Specific Populations (8.7) ].
2.8 hours
- Numeric value
- 2.8
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8425be72-2bbe-4090-b00e-610f1a1646b1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbda91f7-4411-4016-80d6-0a349931956d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c64bc71-2e7f-4b15-a8e1-acb8de04395f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebd6c66b-b230-48d7-b38f-d610b6cb2b6c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a8072-39bf-44c5-e063-6294a90a77c3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90201886-86a5-4c59-a4f1-98270d620731 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facfc337-3447-4052-a9aa-8aa55282a3e3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When Zolpidem Tartrate Extended-Release Tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf9f431-3013-4cfd-ba4d-c4013f20bdab (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac647afe-2fe5-4056-806f-abdd54789b45 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia throug
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d934da3-bd77-4470-e063-6294a90a64f5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When AMBIEN CR was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0085f-d9fe-430a-9bd5-607f607bf7e1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When zolpidem tartrate extended-release was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76ff87e4-3aa2-439d-8436-d9e6affb33c8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35f6c1ab-a61c-4625-b932-11a7483f1d84 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25e71199-c55d-4cc6-8388-b309d654d2b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When zolpidem tartrate extended-release was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08411424-e8a8-4964-bd04-5b0b5aa5baaf (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30c057fb-2e1b-4b9c-8c8a-79c322151e61 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca751bb-5161-5a95-e053-2a95a90aa2dd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625fad5b-8817-4773-a2fc-20b662140e6e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f23bc3-595b-28e5-e053-2a95a90a9c2c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21767f56-ce92-2b8c-e063-6394a90a8b76 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d91478-ea0e-407e-b5cb-0eeb592e0aa4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When Zolpidem Tartrate Extended-Release Tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:604e77ef-2cda-4efc-abfb-9af549d40fd4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia throug
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82bca7a0-021f-4e35-8b3f-6390eeb863a6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When zolpidem tartrate extended-release was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1faca42-6e46-4586-97ac-050b724e7d2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72e19b8e-d13a-4824-aee4-11778eba552c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:028bf425-7a72-464d-a242-aa5deee1ac23 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia throug
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce301d8b-0a8c-4404-8697-57222ae17a44 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When zolpidem tartrate extended-release was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf99cd5c-9671-45a6-bda9-3dfc8252efdd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination When zolpidem tartrate extended-release tablet was administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr). 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia throug
3.70 hours
- Numeric value
- 3.7
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b49f6c18-e155-4728-a79a-9354e8c3c8f4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Excretion Following a single 7.5 mg dose of Zolpidem Tartrate Capsules under fasting state, the mean apparent clearance (CL/F) of the zolpidem tartrate was 15.72 L/hr (range: 5.44 to 96.71), and the mean elimination half-life was 3.70 hours (range: 1.2 to 8.3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9025a6f7-5501-4aba-875e-222ef39848c0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Excretion Following a single 7.5 mg dose of Zolpidem Tartrate Capsules under fasting state, the mean apparent clearance (CL/F) of the zolpidem tartrate was 15.72 L/hr (range: 5.44 to 96.71), and the mean elimination half-life was 3.70 hours (range: 1.2 to 8.3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Excretion Following a single 7.5 mg dose of Zolpidem Tartrate Capsules under fasting state, the mean apparent clearance (CL/F) of the zolpidem tartrate was 15.72 L/hr (range: 5.44 to 96.71), and the mean elimination half-life was 3.70 hours (range: 1.2 to 8.3 hours).
2.85 hours
- Numeric value
- 2.85
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a32884d0-85b5-11de-8a39-0800200c9a66 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Elimination: When Edluar administered as a single 5 or 10 mg dose in healthy adult subjects, the mean zolpidem elimination half-life was 2.85 hours (range: 1.57-6.73 hr) and 2.65 hours (range: 1.75 to 3.77 hr) respectively.
2.9 hours
- Numeric value
- 2.9
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41124767-8ff7-da5d-e063-6394a90a5203 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
The mean AUC of zolpidem was 413 ng∙hr/mL (range: 124 to 1190 ng∙hr/mL) and the mean elimination half-life was 2.9 hours (range: 1.59 to 5.50 hours).
Projected row 1677
- Medicine slug
- zolpidem
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 117
- Source count
- 117
- Agreement rate
- 0.991453
- Recorded readings
92.5 ± 0.1%
- Numeric value
- 92.5
- Unit
- %
- Source records
- 116
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 116 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7abb6898-223c-487b-856c-068ac04f7a5c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c6cc45-c28b-729b-e053-2a95a90a7ccb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:747949c5-2c91-4909-8a07-71b6826f8e97 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8425be72-2bbe-4090-b00e-610f1a1646b1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47212207-52a1-938b-e063-6294a90abca8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67ef513-1b2c-42fe-bf33-4c7e9db191a3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89cfb1d5-437c-4c13-8f9b-b6851ffba87b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abdcf77-d3ed-42bc-acd9-545aab75d567 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbda91f7-4411-4016-80d6-0a349931956d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c64bc71-2e7f-4b15-a8e1-acb8de04395f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e5208b-5109-58c6-e053-2995a90a994a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70d7cfc3-7e54-4cd8-8911-7cf115d5c820 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acfcfe91-83a0-44ab-95c0-dd98b73ac69a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23bce69d-7918-42c2-8020-e22f292ff31f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebd6c66b-b230-48d7-b38f-d610b6cb2b6c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a8072-39bf-44c5-e063-6294a90a77c3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cef5718-c562-43c3-8abe-a2fc5235ad2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc76ab4c-3607-39c3-e053-6394a90a6877 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87b722-cdb7-0b17-e053-2a95a90a315b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90201886-86a5-4c59-a4f1-98270d620731 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413b6f65-101e-e2cf-0802-711d080b851b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0553e26c-f2aa-43aa-adf9-6eb951a501d3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87ae17-a3c5-a3a5-e053-2a95a90aa4b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c859c752-8a85-2017-e053-2a95a90a771f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74c4e793-3444-4d3d-8211-26374349ab1e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facfc337-3447-4052-a9aa-8aa55282a3e3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf9f431-3013-4cfd-ba4d-c4013f20bdab (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaca34da-2b12-4dd4-91b5-a8446c7bd41e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff2e7fc-2f7e-43c9-bfb3-d929ecc9eb72 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac647afe-2fe5-4056-806f-abdd54789b45 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f8488f3-851d-4111-af23-60f420aad0d6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b49f6c18-e155-4728-a79a-9354e8c3c8f4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1584bad1-7bf4-4805-bdd9-7eb0fac92721 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41124767-8ff7-da5d-e063-6394a90a5203 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6ce23-e7b1-510e-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f43bde-efba-42be-adef-94e1ef6664fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2db3979-daa6-6e83-e053-2a95a90a3a2f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d934da3-bd77-4470-e063-6294a90a64f5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0085f-d9fe-430a-9bd5-607f607bf7e1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e15d6e3-8d06-0936-e063-6394a90ab8db (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c58053-7ed8-4a3d-a2f7-8e30c4e5a367 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76ff87e4-3aa2-439d-8436-d9e6affb33c8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5679ed64-8424-4e63-a3c9-91d80fff2ca6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e2d31b-ce26-78b0-e053-2a95a90ac491 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf3dcbde-b92a-4802-98e4-14f00abdf99e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:507225e2-80ba-18c4-e054-00144ff88e88 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cc924a-26e0-431f-9160-32c9d92a46cd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fa86b79-8809-35f4-e063-6394a90a4377 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bbc3c35-2811-4a67-9dcc-5eed38ef8b52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda413e7-b1ae-312a-e053-6394a90ab2c6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a32884d0-85b5-11de-8a39-0800200c9a66 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Based on data obtained with oral zolpidem, the total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91511d2f-7066-49a0-90ea-2940d955c85e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35f6c1ab-a61c-4625-b932-11a7483f1d84 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cc61da-838e-4add-b2d6-42b2b283a000 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76eb9d8-ca7d-4479-bd16-52a57f623b02 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25e71199-c55d-4cc6-8388-b309d654d2b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8581cfad-525b-4b16-b116-a5138d9fda52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33094305-4bbd-4b52-9079-8853d5f83682 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08411424-e8a8-4964-bd04-5b0b5aa5baaf (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8f7696-0d02-dd1f-e063-6394a90a5866 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb850154-4b4b-4d9a-8476-aea1a93fe8d7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba3c29f-3835-4f4f-a39f-56fb42686f5b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3882d72d-686b-406b-e063-6294a90a0b89 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bc8a122-aa21-212c-e063-6394a90a3bda (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30c057fb-2e1b-4b9c-8c8a-79c322151e61 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca751bb-5161-5a95-e053-2a95a90aa2dd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9025a6f7-5501-4aba-875e-222ef39848c0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5cf535-ccdc-ecd7-e063-6394a90a726e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e20f53-c042-eac0-e063-6394a90acfca (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c9a29c-a285-40d0-bf3a-7e8c944ee39c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68a1b3b-b3d1-495e-be46-466113e7dbd6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa7e88b-7929-45ac-9e81-03f4abf28e94 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac8c412a-0f94-7c3a-e053-2995a90afdc7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e13ad50-f846-813a-e063-6294a90a5878 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38c838a4-9943-445a-8e80-e823d56eeaa5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d34336b1-7041-4078-beda-94bc9d9f771e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83510333-f07d-4b81-a3ae-2801d114bd31 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625fad5b-8817-4773-a2fc-20b662140e6e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df130798-1458-455b-a4e1-c33c4ecee43b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e534b3ac-1110-465f-8692-6ea585996fb6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b0ba48-4e71-25f7-e053-2a95a90aea82 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db735db9-1c82-4d32-bf91-97b05a75e876 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8adec28-9dcd-4a7e-e053-2a95a90a991e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9f696a-b637-4dea-e063-6394a90aeb2e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f23bc3-595b-28e5-e053-2a95a90a9c2c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9ac3d4e-f502-41e3-95c0-0d334584566d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21767f56-ce92-2b8c-e063-6394a90a8b76 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8572fd4-70c7-4c94-a0d7-9b4be6fa8f77 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7be7f243-e6f8-406f-aed7-be7cedd5630a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e5b61b6-a5bd-4f09-9d34-905ce32f1899 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea2067bd-1622-4d98-8012-2c09405aa88d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d91478-ea0e-407e-b5cb-0eeb592e0aa4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25f1176d-5195-1a99-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:604e77ef-2cda-4efc-abfb-9af549d40fd4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dd113e1-f789-48d2-8cb2-d39b71273658 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82bca7a0-021f-4e35-8b3f-6390eeb863a6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349053e4-9885-ec0b-e063-6294a90ad79a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1faca42-6e46-4586-97ac-050b724e7d2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72e19b8e-d13a-4824-aee4-11778eba552c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7da75d2b-905c-4fdf-bc53-1358c6477755 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2556c804-7a5e-4dbd-aeef-a3ba3a247c39 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:028bf425-7a72-464d-a242-aa5deee1ac23 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c36cadf4-65a4-4466-b409-c82020b42452 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c108d1-5e2f-41c7-a845-2aed48c30905 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021153ce-fe27-4ed1-8d88-b4157b0ed734 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78481108-4a1c-fce9-e053-2a91aa0a09ad (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce301d8b-0a8c-4404-8697-57222ae17a44 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution: Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87df4e-2c97-e23e-e053-2a95a90ab354 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f939549f-14a6-d37c-e053-6294a90a034a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d579c6ca-c820-49ff-92fb-2e6aaad3b052 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3310d63e-d79a-175d-e063-6394a90a4270 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef72eb73-d058-4ca3-9013-691aae8426fb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:907c7b18-2638-512c-e053-2995a90ae6fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf99cd5c-9671-45a6-bda9-3dfc8252efdd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9922ce14-b418-4235-9c59-d674a8e70210 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
93%
- Numeric value
- 93
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6db679f6-b1f8-4fbf-9e87-9cef4650c45a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Distribution Based on data obtained with oral zolpidem, the total protein binding was found to be 93% ± 0.1% and remained constant independent of concentration between 40 ng/mL and 790 ng/mL.
Projected row 1678
- Medicine slug
- zolpidem
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 117
- Source count
- 109
- Agreement rate
- 0.733945
- Recorded readings
1.6 hours
- Numeric value
- 1.6
- Unit
- hours
- Source records
- 80
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 80 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7abb6898-223c-487b-856c-068ac04f7a5c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c6cc45-c28b-729b-e053-2a95a90a7ccb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47212207-52a1-938b-e063-6294a90abca8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67ef513-1b2c-42fe-bf33-4c7e9db191a3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89cfb1d5-437c-4c13-8f9b-b6851ffba87b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abdcf77-d3ed-42bc-acd9-545aab75d567 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e5208b-5109-58c6-e053-2995a90a994a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70d7cfc3-7e54-4cd8-8911-7cf115d5c820 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acfcfe91-83a0-44ab-95c0-dd98b73ac69a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23bce69d-7918-42c2-8020-e22f292ff31f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cef5718-c562-43c3-8abe-a2fc5235ad2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc76ab4c-3607-39c3-e053-6394a90a6877 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87b722-cdb7-0b17-e053-2a95a90a315b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413b6f65-101e-e2cf-0802-711d080b851b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0553e26c-f2aa-43aa-adf9-6eb951a501d3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87ae17-a3c5-a3a5-e053-2a95a90aa4b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c859c752-8a85-2017-e053-2a95a90a771f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74c4e793-3444-4d3d-8211-26374349ab1e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaca34da-2b12-4dd4-91b5-a8446c7bd41e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff2e7fc-2f7e-43c9-bfb3-d929ecc9eb72 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f8488f3-851d-4111-af23-60f420aad0d6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1584bad1-7bf4-4805-bdd9-7eb0fac92721 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6ce23-e7b1-510e-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f43bde-efba-42be-adef-94e1ef6664fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2db3979-daa6-6e83-e053-2a95a90a3a2f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e15d6e3-8d06-0936-e063-6394a90ab8db (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c58053-7ed8-4a3d-a2f7-8e30c4e5a367 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5679ed64-8424-4e63-a3c9-91d80fff2ca6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e2d31b-ce26-78b0-e053-2a95a90ac491 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf3dcbde-b92a-4802-98e4-14f00abdf99e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:507225e2-80ba-18c4-e054-00144ff88e88 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67cc924a-26e0-431f-9160-32c9d92a46cd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fa86b79-8809-35f4-e063-6394a90a4377 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bbc3c35-2811-4a67-9dcc-5eed38ef8b52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda413e7-b1ae-312a-e053-6394a90ab2c6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91511d2f-7066-49a0-90ea-2940d955c85e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cc61da-838e-4add-b2d6-42b2b283a000 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76eb9d8-ca7d-4479-bd16-52a57f623b02 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8581cfad-525b-4b16-b116-a5138d9fda52 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33094305-4bbd-4b52-9079-8853d5f83682 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8f7696-0d02-dd1f-e063-6394a90a5866 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb850154-4b4b-4d9a-8476-aea1a93fe8d7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ba3c29f-3835-4f4f-a39f-56fb42686f5b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3882d72d-686b-406b-e063-6294a90a0b89 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bc8a122-aa21-212c-e063-6394a90a3bda (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5cf535-ccdc-ecd7-e063-6394a90a726e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e20f53-c042-eac0-e063-6394a90acfca (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c9a29c-a285-40d0-bf3a-7e8c944ee39c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68a1b3b-b3d1-495e-be46-466113e7dbd6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa7e88b-7929-45ac-9e81-03f4abf28e94 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac8c412a-0f94-7c3a-e053-2995a90afdc7 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e13ad50-f846-813a-e063-6294a90a5878 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38c838a4-9943-445a-8e80-e823d56eeaa5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d34336b1-7041-4078-beda-94bc9d9f771e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83510333-f07d-4b81-a3ae-2801d114bd31 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df130798-1458-455b-a4e1-c33c4ecee43b (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e534b3ac-1110-465f-8692-6ea585996fb6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b0ba48-4e71-25f7-e053-2a95a90aea82 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8adec28-9dcd-4a7e-e053-2a95a90a991e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9f696a-b637-4dea-e063-6394a90aeb2e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9ac3d4e-f502-41e3-95c0-0d334584566d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8572fd4-70c7-4c94-a0d7-9b4be6fa8f77 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7be7f243-e6f8-406f-aed7-be7cedd5630a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e5b61b6-a5bd-4f09-9d34-905ce32f1899 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea2067bd-1622-4d98-8012-2c09405aa88d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25f1176d-5195-1a99-e054-00144ff8d46c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dd113e1-f789-48d2-8cb2-d39b71273658 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349053e4-9885-ec0b-e063-6294a90ad79a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7da75d2b-905c-4fdf-bc53-1358c6477755 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2556c804-7a5e-4dbd-aeef-a3ba3a247c39 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c108d1-5e2f-41c7-a845-2aed48c30905 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021153ce-fe27-4ed1-8d88-b4157b0ed734 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Tartrate Tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78481108-4a1c-fce9-e053-2a91aa0a09ad (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af87df4e-2c97-e23e-e053-2a95a90ab354 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f939549f-14a6-d37c-e053-6294a90a034a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d579c6ca-c820-49ff-92fb-2e6aaad3b052 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3310d63e-d79a-175d-e063-6394a90a4270 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef72eb73-d058-4ca3-9013-691aae8426fb (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:907c7b18-2638-512c-e053-2995a90ae6fd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max) of 1.6 hours for both.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9922ce14-b418-4235-9c59-d674a8e70210 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C max ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T max ) of 1.6 hours for both.
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 29
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 29 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8425be72-2bbe-4090-b00e-610f1a1646b1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbda91f7-4411-4016-80d6-0a349931956d (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Figure 1 Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c64bc71-2e7f-4b15-a8e1-acb8de04395f (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebd6c66b-b230-48d7-b38f-d610b6cb2b6c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a8072-39bf-44c5-e063-6294a90a77c3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90201886-86a5-4c59-a4f1-98270d620731 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facfc337-3447-4052-a9aa-8aa55282a3e3 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption: Following administration of Zolpidem Tartrate Extended-Release Tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf9f431-3013-4cfd-ba4d-c4013f20bdab (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac647afe-2fe5-4056-806f-abdd54789b45 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41124767-8ff7-da5d-e063-6394a90a5203 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Zolpidem Plasma Graph.jpg Absorption Following administration of Zolpidem Tartrate, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d934da3-bd77-4470-e063-6294a90a64f5 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Figure 1 Absorption Following administration of AMBIEN CR, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0085f-d9fe-430a-9bd5-607f607bf7e1 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption: Following administration of zolpidem tartrate extended-release, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/mL) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76ff87e4-3aa2-439d-8436-d9e6affb33c8 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35f6c1ab-a61c-4625-b932-11a7483f1d84 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Figure 1 Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25e71199-c55d-4cc6-8388-b309d654d2b0 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption: Following administration of zolpidem tartrate extended-release, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08411424-e8a8-4964-bd04-5b0b5aa5baaf (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30c057fb-2e1b-4b9c-8c8a-79c322151e61 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca751bb-5161-5a95-e053-2a95a90aa2dd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625fad5b-8817-4773-a2fc-20b662140e6e (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f23bc3-595b-28e5-e053-2a95a90a9c2c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (Cmax) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (Tmax) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21767f56-ce92-2b8c-e063-6394a90a8b76 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d91478-ea0e-407e-b5cb-0eeb592e0aa4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Figure 1 Absorption Following administration of Zolpidem Tartrate Extended-Release Tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:604e77ef-2cda-4efc-abfb-9af549d40fd4 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82bca7a0-021f-4e35-8b3f-6390eeb863a6 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption: Following administration of zolpidem tartrate extended-release, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/mL) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1faca42-6e46-4586-97ac-050b724e7d2a (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72e19b8e-d13a-4824-aee4-11778eba552c (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:028bf425-7a72-464d-a242-aa5deee1ac23 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce301d8b-0a8c-4404-8697-57222ae17a44 (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption: Following administration of zolpidem tartrate extended-release, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/mL) occurring at a median time (T max ) of 1.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf99cd5c-9671-45a6-bda9-3dfc8252efdd (opens source in a new tab)
Zolpidem label
Version not recorded · Effective date not recorded
Absorption Following administration of zolpidem tartrate extended-release tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C max ) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T max ) of 1.5 hours.
Projected row 1679
- Medicine slug
- zonisamide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 33
- Source count
- 33
- Agreement rate
- 1
- Recorded readings
63 hours
- Numeric value
- 63
- Unit
- hours
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:467a73f0-1cd1-46bf-83b3-ee38badb761c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe15e56e-8b86-4a65-825c-31d37dd81612 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3164d438-90bf-420a-9a56-5498b987f91c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d569c8a-844b-44a8-81df-3f9c9300a79c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b059f0-a08a-f75a-e063-6294a90a57db (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8f368cb-6a07-4178-95fa-1d5a209171ed (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cdd96c4-3263-4c28-86c0-3c24bcef16c1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ecba6c-0de4-4e11-81d5-6deac79accd5 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40094d96-e979-4b3e-840f-a96677480f96 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c53d5e4-f47f-46fd-aa1c-158fd49ba9c0 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a859304-804a-4588-9961-c2e6ae09aadb (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5000f95c-c78d-4150-9a69-0ee2943cf2c3 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d12de43e-3ac3-4335-bc85-70d7366a91eb (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35bcaee1-001f-82da-e063-6394a90a4a0f (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85321a9a-08d9-49e4-8c79-86ecfc536613 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4b0ee6a-d4cf-4f29-b9ff-fd5ffc1ce7e1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:061fdccc-d08e-4e42-8a32-54afb6c89701 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33b84aaa-044d-4c15-bb21-d1ce8674eec9 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab0631ca-5339-4570-bc27-f1dd92de1d6f (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24284954-0c29-458f-a9f8-97a7ad418ca7 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bc550a7-09a7-75e4-e063-6294a90a9fc1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64bd9d6f-8cc0-4151-a78d-9f1437b36875 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812582ce-fc7e-44b1-a428-7faa3701c1b8 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ab5b6aa-4bdc-4ec6-ba23-44caf2db953e (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:226d917a-33de-48cc-baf6-bd6a20668341 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20a51ef-255e-1eb0-c0e1-461cde46b887 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is about 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994e3ce0-f30b-47b1-aa42-b1ed37fb7c12 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:597f0a0b-e162-497c-9871-f2b73ebad245 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64b78d8-79de-337b-e053-2a95a90a4861 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac16fa15-32e9-4f92-8bc6-d8d41ae002c6 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Excretion The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:345efcc4-6a36-4ddf-8b6c-9c6c844dab0a (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50bb1a0a-a66d-4a13-a456-a10c1b8c8e94 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
The elimination half-life of zonisamide in plasma is approximately 63 hours.
Projected row 1680
- Medicine slug
- zonisamide
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 33
- Source count
- 33
- Agreement rate
- 0.969697
- Recorded readings
2 to 6 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 32
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 32 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:467a73f0-1cd1-46bf-83b3-ee38badb761c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe15e56e-8b86-4a65-825c-31d37dd81612 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3164d438-90bf-420a-9a56-5498b987f91c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d569c8a-844b-44a8-81df-3f9c9300a79c (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b059f0-a08a-f75a-e063-6294a90a57db (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8f368cb-6a07-4178-95fa-1d5a209171ed (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cdd96c4-3263-4c28-86c0-3c24bcef16c1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ecba6c-0de4-4e11-81d5-6deac79accd5 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40094d96-e979-4b3e-840f-a96677480f96 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c53d5e4-f47f-46fd-aa1c-158fd49ba9c0 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a859304-804a-4588-9961-c2e6ae09aadb (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5000f95c-c78d-4150-9a69-0ee2943cf2c3 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d12de43e-3ac3-4335-bc85-70d7366a91eb (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 µg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35bcaee1-001f-82da-e063-6394a90a4a0f (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85321a9a-08d9-49e4-8c79-86ecfc536613 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4b0ee6a-d4cf-4f29-b9ff-fd5ffc1ce7e1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:061fdccc-d08e-4e42-8a32-54afb6c89701 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33b84aaa-044d-4c15-bb21-d1ce8674eec9 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab0631ca-5339-4570-bc27-f1dd92de1d6f (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24284954-0c29-458f-a9f8-97a7ad418ca7 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bc550a7-09a7-75e4-e063-6294a90a9fc1 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64bd9d6f-8cc0-4151-a78d-9f1437b36875 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812582ce-fc7e-44b1-a428-7faa3701c1b8 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ab5b6aa-4bdc-4ec6-ba23-44caf2db953e (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics Absorption Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2 mcg/mL to 5 mcg/mL) in normal volunteers occur within 2-6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:226d917a-33de-48cc-baf6-bd6a20668341 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20a51ef-255e-1eb0-c0e1-461cde46b887 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994e3ce0-f30b-47b1-aa42-b1ed37fb7c12 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:597f0a0b-e162-497c-9871-f2b73ebad245 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64b78d8-79de-337b-e053-2a95a90a4861 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:345efcc4-6a36-4ddf-8b6c-9c6c844dab0a (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50bb1a0a-a66d-4a13-a456-a10c1b8c8e94 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
Pharmacokinetics: Absorption Following a 200 to 400 mg oral zonisamide dose, peak plasma concentrations (range: 2 to 5 mcg/mL) in normal volunteers occur within 2 to 6 hours.
0.5–5 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac16fa15-32e9-4f92-8bc6-d8d41ae002c6 (opens source in a new tab)
Zonisamide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following a 100 mg ZONISADE dose in normal volunteers, the time to maximum plasma concentrations (T max ) occurred within 0.5–5 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1670Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.